Biomaterial Database

Overcoming Waning Immunity in Pertussis Vaccines: Workshop of the National Institute of Allergy and Infectious Diseases. 2020

F Heath Damron, and Mariette Barbier, and Purnima Dubey, and Kathryn M Edwards, and Xin-Xing Gu, and Nicola P Klein, and Kristina Lu, and Kingston H G Mills, and Marcela F Pasetti, and Robert C Read, and Pejman Rohani, and Peter Sebo, and Eric T Harvill

Department of Microbiology, Immunology, and Cell Biology and Vaccine Development Center at West Virginia University Health Sciences Center, West Virginia University, Morgantown, WV 26506.

Despite high vaccine coverage in many parts of the world, pertussis is resurging in a number of areas in which acellular vaccines are the primary vaccine administered to infants and young children. This is attributed in part to the suboptimal and short-lived immunity elicited by acellular pertussis vaccines and to their inability to prevent nasal colonization and transmission of the etiologic agent Bordetella pertussis In response to this escalating public health concern, the National Institute of Allergy and Infectious Diseases held the workshop "Overcoming Waning Immunity in Pertussis Vaccines" in September 2019 to identify issues and possible solutions for the defects in immunity stimulated by acellular pertussis vaccines. Discussions covered aspects of the current problem, gaps in knowledge and possible paths forward. This review summarizes presentations and discussions of some of the key points that were raised by the workshop.

UI	MeSH Term	Description	Entries
D010567	Pertussis Vaccine	A suspension of killed Bordetella pertussis organisms, used for immunization against pertussis (WHOOPING COUGH). It is generally used in a mixture with diphtheria and tetanus toxoids (DTP). There is an acellular pertussis vaccine prepared from the purified antigenic components of Bordetella pertussis, which causes fewer adverse reactions than whole-cell vaccine and, like the whole-cell vaccine, is generally used in a mixture with diphtheria and tetanus toxoids. (From Dorland, 28th ed)	Vaccine, Pertussis
D001886	Bordetella pertussis	A species of gram-negative, aerobic bacteria that is the causative agent of WHOOPING COUGH. Its cells are minute coccobacilli that are surrounded by a slime sheath.	Bacterium tussis-convulsivae,Haemophilus pertussis,Hemophilus pertussis
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818	Animals	Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA.	Animal,Metazoa,Animalia
D014481	United States	A country in NORTH AMERICA between CANADA and MEXICO.
D014917	Whooping Cough	A respiratory infection caused by BORDETELLA PERTUSSIS and characterized by paroxysmal coughing ending in a prolonged crowing intake of breath.	Pertussis,Bordetella pertussis Infection, Respiratory,Cough, Whooping,Pertusses
D054579	National Institute of Allergy and Infectious Diseases (U.S.)	Component of the NATIONAL INSTITUTES OF HEALTH. It conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases. It was established in 1948.	NIAID,National Institute of Allergy and Infectious Diseases
D022282	Vaccines, Acellular	Vaccines that are produced by using only the antigenic part of the disease causing organism. They often require a "booster" every few years to maintain their effectiveness.	Acellular Vaccine,Acellular Vaccines,Vaccine, Acellular